Clinical trials have shown that anti-VEGF drugs, administered either as monotherapy or in combination with chemotherapy or radiation therapy, merely slowed down tumor progression, significantly prolonging only progression free survival (PFS), without improving overall survival (OS) in these individuals [7, 8]. This evidence concerns the gene VEGFA and neoplasm.